Download
s40035-021-00257-y.pdf 2,46MB
WeightNameValue
1000 Titel
  • Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials
1000 Autor/in
  1. Witzel, Simon |
  2. Frauhammer, Felix |
  3. Steinacker, Petra |
  4. Devos, David |
  5. Pradat, Pierre-François |
  6. Meininger, Vincent |
  7. Halbgebauer, Steffen |
  8. Oeckl, Patrick |
  9. Schuster, Joachim |
  10. Anders, Simon |
  11. Dorst, Johannes |
  12. Otto, Markus |
  13. Ludolph, Albert C. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-08-26
1000 Erschienen in
1000 Quellenangabe
  • 10(1):31
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s40035-021-00257-y |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390195/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Interventional trials in amyotrophic lateral sclerosis (ALS) suffer from the heterogeneity of the disease as it considerably reduces statistical power. We asked if blood neurofilament light chains (NfL) could be used to anticipate disease progression and increase trial power.!##!Methods!#!In 125 patients with ALS from three independent prospective studies-one observational study and two interventional trials-we developed and externally validated a multivariate linear model for predicting disease progression, measured by the monthly decrease of the ALS Functional Rating Scale Revised (ALSFRS-R) score. We trained the prediction model in the observational study and tested the predictive value of the following parameters assessed at diagnosis: NfL levels, sex, age, site of onset, body mass index, disease duration, ALSFRS-R score, and monthly ALSFRS-R score decrease since disease onset. We then applied the resulting model in the other two study cohorts to assess the actual utility for interventional trials. We analyzed the impact on trial power in mixed-effects models and compared the performance of the NfL model with two currently used predictive approaches, which anticipate disease progression using the ALSFRS-R decrease during a three-month observational period (lead-in) or since disease onset (ΔFRS).!##!Results!#!Among the parameters provided, the NfL levels (P < 0.001) and the interaction with site of onset (P < 0.01) contributed significantly to the prediction, forming a robust NfL prediction model (R = 0.67). Model application in the trial cohorts confirmed its applicability and revealed superiority over lead-in and ΔFRS-based approaches. The NfL model improved statistical power by 61% and 22% (95% confidence intervals: 54%-66%, 7%-29%).!##!Conclusion!#!The use of the NfL-based prediction model to compensate for clinical heterogeneity in ALS could significantly increase the trial power. NCT00868166, registered March 23, 2009; NCT02306590, registered December 2, 2014.
1000 Sacherschließung
lokal Female [MeSH]
lokal Disease Progression [MeSH]
lokal Amyotrophic lateral sclerosis
lokal Disease progression
lokal Aged [MeSH]
lokal Biomarkers/blood [MeSH]
lokal Humans [MeSH]
lokal Prediction model
lokal Prospective Studies [MeSH]
lokal Predictive Value of Tests [MeSH]
lokal Amyotrophic Lateral Sclerosis/blood [MeSH]
lokal Middle Aged [MeSH]
lokal Statistical power
lokal Cohort Studies [MeSH]
lokal Amyotrophic Lateral Sclerosis/diagnosis [MeSH]
lokal Models, Neurological [MeSH]
lokal Interventional trials
lokal Male [MeSH]
lokal Neurofilament Proteins/blood [MeSH]
lokal Reproducibility of Results [MeSH]
lokal Research
lokal Neurofilament light
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-1841-954X|https://frl.publisso.de/adhoc/uri/RnJhdWhhbW1lciwgRmVsaXg=|https://frl.publisso.de/adhoc/uri/U3RlaW5hY2tlciwgUGV0cmE=|https://frl.publisso.de/adhoc/uri/RGV2b3MsIERhdmlk|https://frl.publisso.de/adhoc/uri/UHJhZGF0LCBQaWVycmUtRnJhbsOnb2lz|https://frl.publisso.de/adhoc/uri/TWVpbmluZ2VyLCBWaW5jZW50|https://frl.publisso.de/adhoc/uri/SGFsYmdlYmF1ZXIsIFN0ZWZmZW4=|https://frl.publisso.de/adhoc/uri/T2Vja2wsIFBhdHJpY2s=|https://frl.publisso.de/adhoc/uri/U2NodXN0ZXIsIEpvYWNoaW0=|https://frl.publisso.de/adhoc/uri/QW5kZXJzLCBTaW1vbg==|https://frl.publisso.de/adhoc/uri/RG9yc3QsIEpvaGFubmVz|https://frl.publisso.de/adhoc/uri/T3R0bywgTWFya3Vz|https://frl.publisso.de/adhoc/uri/THVkb2xwaCwgQWxiZXJ0IEMu
1000 Hinweis
  • DeepGreen-ID: a3994611147344d299728986653a5b3b ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6464407.rdf
1000 Erstellt am 2023-11-16T03:29:45.199+0100
1000 Erstellt von 322
1000 beschreibt frl:6464407
1000 Zuletzt bearbeitet 2023-11-30T23:50:07.692+0100
1000 Objekt bearb. Thu Nov 30 23:50:07 CET 2023
1000 Vgl. frl:6464407
1000 Oai Id
  1. oai:frl.publisso.de:frl:6464407 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source